STILDEP: Zolpidem in Depressive and Dysthimic Patients
Sleep Initiation and Maintenance Disorders, Depression
About this trial
This is an interventional treatment trial for Sleep Initiation and Maintenance Disorders
Eligibility Criteria
Inclusion Criteria: Depressive and dysthimic patients in acute phase of mild to moderate severity Depressive and dysthimic patients suffering from secondary insomnia (DSM IV) recent antidepressant therapy (less than 1 week) Exclusion Criteria: Regularly use of sleeping pills in the last 2-3 month Use of any sleeping pils in the last week Insufficient hepatic Myasthenia gravis Proven hypersensivity to Zolpidem Evidence of clinically relevant nervous system disorders (other neurologic/psychiatric diseases associated with depression) History of evidence of alcohol or drug abuse Evidence of clinically relevant cardiovascular, haematologic, hepatic, gastrointestinal, renal, pulmonary or endocrinologic diseases Abnormal snore Work an alternating shift Suffering from periodic leg movement disorder and sleep apnea
Sites / Locations
- Sanofi-Aventis